Cost Considerations for the Application of Continuous Processing
02nd October 2019 | 3:00 PM India Standard Time/ 10:30 AM GMT | Narasimha Rao Nedunuri, CEO of CLONZ Biotech |BOOK FREE SEAT
- Cost contribution of continuous manufacturing both in operational and capital expenditure in Monoclonal antibody production.
- Evaluating cost of production per gram conventional fed batch vs continuous process.
- Key considerations for adapting continuous process for the production of Biosimilar MAbs.
Presented by Narasimha Rao Nedunuri, CEO of CLONZ Biotech
Narasimha Rao Nedunuri is one of the founding members of CLONZ Biotech, a Biosimilar Monoclonal Antibody company based in Genome Valley, Hyderabad, India.
He is currently serving the company as the Managing Director & CEO .
Nedunuri, a Molecular Biologist turned Entrepreneur has 18 years of experience in the field of Life Sciences Research including Cancer Biology, Proteomics, and Molecular diagnostics. He also had business experience in a USA based company, with the responsibility of establishing a business division for its Indian subsidiary.
At CLONZ , a 7 year old start-up, along with the co-promoters coming from recognized leaders who launched complex Biosimilar MAbs, driving the company to emerge as a significant Global Biosimilar MAb company.